U.S. Markets close in 6 hrs 3 mins

Cannabis and Biotech Stocks that Could Explode

HENDERSON, NV / ACCESSWIRE / January 29, 2019 / Small cap securities in the biotechnology industry are always of interest to investors because several events can help increase the stock's share price at a breakneck pace. That's why investors are always searching for the next 'big thing' that could either become FDA approved, acquired, or just make major progress. The companies below are the kinds of opportunities these investors crave.

One company who's on the verge of a major breakthrough, BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, is developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue. The stock is still relatively unknown, however, with the global obesity treatment market expected to reach $15.6 billion by 2024 you can bet investors will be very interested in this company when they learn about it. Get a jumpstart on the crowd by researching BRTX today.

Today we are highlighting: BioRestorative Therapies, Inc. (BRTX), Aurora Cannabis, Inc. (ACB), Cannabix Pharmaceuticals, Inc. (CNBX), Cara Therapeutics, Inc. (CARA), and Celldex Therapeutics, Inc. (CLDX).

According to Grand View Research, the global obesity treatment market was valued at $3.9 billion in 2015 and is expected to reach $15.6 billion by 2024. According to the Institute of Health Metrics and Evaluation, about 30% of the global population is either obese or overweight. These are just a couple making companies developing weight management solutions so valuable to investors.

One of the more novel approaches to fighting this obesity epidemic is being developed by BioRestorative Therapies, Inc. (BRTX) (Market Cap: $7.669M, Share Price: $0.60), a life sciences company focused on stem cell-based therapies, developing a therapy "ThermoStem" using brown adipose (fat) derived stem cells to generate brown adipose tissue ("BAT"). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans.

BRTX just received a Notice of Allowance on the company's fourth patent for their metabolic ThermoStem program. The company's patents span US, Australia and Japan.

Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. This is a very promising sign for the company.

____

Aurora Cannabis, Inc. (ACB) (Market Cap: $6.593B, Share Price: $6.62) provided an expected revenue range for the second quarter of the Company's Fiscal 2019, the period ended December 31, 2018. They are anticipating net revenues of $50M to $55M. Full results will be published on Monday, February 11, 2019 pre-market.

____

Cannabics Pharmaceuticals, Inc. (CNBX) (Market Cap: $58.319M, Share Price: $0.4420) announced that along with NewCanna Hub, a world leader in the field of cannabinoids, have signed a non-binding letter of intent at The World Economic Forum in Davos, Switzerland, to establish an equal joint venture that is intended to produce and market Cannabics' Slow Release ("SR") capsules in Colombia and potentially other regulated markets. Pursuant to the terms of the LOI, the parties intend to develop a joint business plan for the joint venture within the next 30 days and execute a definitive joint venture agreement as soon as reasonably practicable.

____

Cara Therapeutics, Inc. (CARA) (Market Cap: $584.602M, Share Price: $14.82) announced completion of enrollment in the KALM-1 Phase 3 trial of KORSUVA™ (CR845/ difelikefalin) Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). More than 350 hemodialysis patients with CKD-aP have now been randomized across approximately 60 clinical sites in the United States.

____

Celldex Therapeutics, Inc. (CLDX) (Market Cap: $57.604M, Share Price: $0.3340) presented data from the Company's MerTK antibody program in a poster session today at the Society for Immunotherapy of Cancer's (SITC) 33rdAnnual Meeting. MerTK is emerging as a promising target for cancer immunotherapy.

____

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to receive a $90,000 convertible note with the issuer for 90 days of service dated 7/10/18. Regal Consulting has signed an amendment to the agreement dated 7/10/18, to extend the agreement and provide additional services for an additional $80,000 convertible note with the issuer. Regal Consulting has signed a second amendment to add additional services for an additional $90,000 convertible note. All payments were made directly by BioRestorative Therapies, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. BRTX was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Microcap Speculators